Actively Recruiting
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
Led by Rutgers, The State University of New Jersey · Updated on 2026-02-23
385
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
Sponsors
R
Rutgers, The State University of New Jersey
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health care settings where melanoma survivors receive follow-up care. A type 1 hybrid effectiveness-implementation design allows us to engage multilevel stakeholders throughout this process, evaluate the effectiveness of the enhanced MSS, and identify critical factors for wide-scale implementation. Aim 1 will focus on enhancing the previous version of MSS by collaborating with multi-level stakeholders in qualitative interviews and usability testing. Aim 2 will evaluate the effects of enhanced MSS on thorough skin-self examinations (SSE) in a randomized-control trial (RCT) and examine its impact on the diagnosis of new/recurrent melanomas. Aim 3 will focus on assessing selected implementation outcomes and identify factors relevant to future scale-up for widespread dissemination and implementation.
CONDITIONS
Official Title
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma
- Three months to five years post-surgery
- No current evidence of cancer
- Not adherent to thorough skin self-examination (did not check entire body at least once during the past three months)
- 18 years old or older
- Access to the internet
- Able to speak and read English
- Able to provide informed consent
You will not qualify if you...
- Children
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
Research Team
S
Sharon Manne, PhD
CONTACT
C
Carolyn Heckman, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
SCREENING
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here